Protagonist Therapeutics Inc PTGX:NASDAQ

Protagonist Therapeutics (PTGX) shares slumped 49% amid heavy trading after the company reported topline data from a phase 2 trial of PN-943 in ulcerative colitis.

More than 5.24 million shares of the company had traded by Tuesday afternoon compared with its daily average of over 801,000.

ERYTECH Pharma (ERYP) disclosed the sale of its US manufacturing facility at Princeton, New Jersey, to Catalent for $44.5 million.

The two firms also plan to sign a "long-term" supply agreement under which Catalent will manufacture ERYTECH's lead product candidate, eryaspase, for clinical and commercial supply in the US.

Shares of ERYTECH fell 21% as trading volume increased to over 1.17 million from its daily average of almost 899,000.

General Electric (GE) said 2022 results would likely come in at the bottom end of its guidance due to growing cost pressure and weakness in the renewable energy division, while external factors capped revenue gains in the first quarter.

Shares dropped 11% as intraday volume soared to over 18.8 million from its daily average of about 6.24 million.